New drugs help Pfizer beat expectations

Sales of breast cancer treatment more than tripled in Q2

2nd August, 2016
Pfizer employs around 3,000 in Ireland Pic:

Pharmaceutical giant Pfizer has reported second-quarter earnings that beat analysts’ estimates, thanks to strong sales of its newest drugs for cancer and rheumatoid arthritis.

Sales of Ibrance, Pfizer’s new breast cancer treatment, more than tripled to $514m. The drug generated $723m last year, its first on the market, and analysts surveyed by Bloomberg predict annual sales will reach $4.81 billion by 2018.

Second-quarter sales of Pfizer’s rheumatoid arthritis drug Xeljanz were $217m, ahead of...

Subscribe from just €1 for the first month!


What's Included

With any subscription you will have access to

  • 971569B3-2C5E-4C45-B798-CEADE16987A8

    Unlimited multi-device access to our iPad, iPhone and Android Apps

  • 099C8662-C57C-42F2-9426-F2F90DF17C8F

    Unlimited access to our eReader library

  • 198AE43B-B9CF-4892-8769-D63C2104BA08

    Exclusive daily insight and opinion seven days a week

  • D8F37B78-25E4-4E4A-A376-4F5789B1564A

    Create alerts to never miss a subject that matters to you

  • B15F2521-37CD-4E02-B898-730A20D39F7F

    Get access to exclusive offers for subscribers on gifts and experiences

  • A564FE02-1AB8-4579-AF9D-BA32A2E5ACA7

    Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine

Share this post

Related Stories

Analysis: At what point could Covid-19 be reasonably compared to a cold or flu?

Ten steps to save yourself at least €5,000 in 2022

Dan O’Brien: Our national inferiority complex fuels the move towards angry populism

Aidan Regan: ‘One size fits all’ doesn’t work for Europe’s many varieties of capitalism